Rezpegaldesleukin is under clinical development by Nektar Therapeutics and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase I drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rezpegaldesleukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NKTR-358 is under development for the treatment of immunological disorders including atopic dermatitis and plaque psoriasis. It is a recombinant protein administered through subcutaneous route. It acts by targeting interleukin 2 receptor subunit alpha and gamma.
It was also under development for the treatment of ulcerative colitis and systemic lupus erythematosus (SLE).
Nektar Therapeutics overview
Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of a wide range of molecules including large classes of drugs targeting numerous disease areas. The company’s products focus on various disease areas including cancer, pain, infections, and immunology among others. Its research and development involve peptides, proteins, antibodies, small molecule drugs, and other potential biological drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.
For a complete picture of Rezpegaldesleukin’s drug-specific PTSR and LoA scores, buy the report here.